Krystal Biotech Past Earnings Performance
Past criteria checks 2/6
Krystal Biotech has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 98.6% per year. Krystal Biotech's return on equity is 5.9%, and it has net margins of 21.7%.
Key information
10.2%
Earnings growth rate
12.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 98.6% |
| Return on equity | 5.9% |
| Net Margin | 21.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Krystal Biotech, Inc. (NASDAQ:KRYS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 07
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Revenue & Expenses Breakdown
How Krystal Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 242 | 52 | 107 | 51 |
| 30 Jun 24 | 166 | 106 | 102 | 49 |
| 31 Mar 24 | 96 | 57 | 100 | 45 |
| 31 Dec 23 | 51 | 11 | 98 | 46 |
| 30 Sep 23 | 9 | -30 | 98 | 46 |
| 30 Jun 23 | 0 | -140 | 94 | 47 |
| 31 Mar 23 | 0 | -135 | 86 | 45 |
| 31 Dec 22 | 0 | -140 | 79 | 42 |
| 30 Sep 22 | 0 | -130 | 69 | 41 |
| 30 Jun 22 | 0 | -115 | 59 | 35 |
| 31 Mar 22 | 0 | -104 | 51 | 31 |
| 31 Dec 21 | 0 | -70 | 42 | 28 |
| 30 Sep 21 | 0 | -58 | 32 | 25 |
| 30 Jun 21 | 0 | -52 | 27 | 24 |
| 31 Mar 21 | 0 | -43 | 21 | 21 |
| 31 Dec 20 | 0 | -32 | 15 | 18 |
| 30 Sep 20 | 0 | -27 | 12 | 17 |
| 30 Jun 20 | 0 | -22 | 9 | 15 |
| 31 Mar 20 | 0 | -20 | 7 | 16 |
| 31 Dec 19 | 0 | -19 | 6 | 16 |
| 30 Sep 19 | 0 | -17 | 6 | 14 |
| 30 Jun 19 | 0 | -16 | 6 | 12 |
| 31 Mar 19 | 0 | -13 | 5 | 9 |
| 31 Dec 18 | 0 | -11 | 4 | 8 |
| 30 Sep 18 | 0 | -9 | 3 | 6 |
| 30 Jun 18 | 0 | -11 | 3 | 5 |
| 31 Mar 18 | 0 | -10 | 2 | 4 |
| 31 Dec 17 | 0 | -8 | 2 | 3 |
| 30 Sep 17 | 0 | -7 | 1 | 3 |
| 30 Jun 17 | 0 | -2 | 1 | 1 |
Quality Earnings: KRYS has a large one-off loss of $37.5M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: KRYS became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRYS has become profitable over the past 5 years, growing earnings by 10.2% per year.
Accelerating Growth: KRYS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: KRYS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KRYS's Return on Equity (5.9%) is considered low.